BioSig (BSGM) 10-Q 15 Apr 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 15, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,211,063
Amendment Flag	false
Entity Central Index Key	0001530766
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 10,933,593	$ 4,450,160
Prepaid expenses	156,577	178,442
Total current assets	11,090,170	4,628,602
Property and equipment, net	53,559	44,346
Right-to-use assets, net	380,586	0
Other assets:
Patents, net	324,397	268,796
Trademarks	1,125	850
Deposits	54,238	54,238
Total assets	11,904,075	4,996,832
Current liabilities:
Accounts payable and accrued expenses, including $14,632 and $32,366 to related parties as of March 31, 2019 and December 31, 2018, respectively	597,006	954,655
Dividends payable	253,449	242,908
Lease liability, short term	158,836	0
Total current liabilities	1,009,291	1,197,563
Lease liability, long term	226,531	0
Total debt	1,235,822	1,197,563
Convertible Preferred Stock	475,000	475,000
Stockholders' equity
Preferred stock	0	0
Common stock, $0.001 par value, authorized 200,000,000 shares, 20,009,985 and 16,868,783 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	20,010	16,869
Additional paid in capital	86,465,732	74,039,341
Common stock subscription	309,000	0
Accumulated deficit	(76,601,489)	(70,731,941)
Total stockholders' equity (deficit)	10,193,253	3,324,269
Total liabilities and stockholders' equity (deficit)	$ 11,904,075	$ 4,996,832

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accounts payable and accrued expenses, related parties (in Dollars)	$ 14,632	$ 32,366
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	20,009,985	16,868,783
Common stock, shares outstanding	20,009,985	16,868,783
Series C Preferred Stock [Member]
Preferred stock, shares issued	475	475
Preferred stock, shares outstanding	475	475
Preferred stock, liquidation preference (in Dollars)	$ 475,000	$ 475,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series D Preferred Stock [Member]
Preferred stock, shares authorized	1,400	1,400
Series E Preferred Stock [Member]
Preferred stock, shares authorized	1,000	1,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 1,488,839	$ 862,420
General and administrative	4,378,897	1,771,796
Depreciation and amortization	7,935	2,903
Total operating expenses	5,875,671	2,637,119
Loss from operations	(5,875,671)	(2,637,119)
Other income (expense):
Interest income	6,123	85
Loss before income taxes	(5,869,548)	(2,637,034)
Income taxes (benefit)	0	0
Net loss	(5,869,548)	(2,637,034)
Preferred stock dividend	(10,541)	(305,046)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (5,880,089)	$ (2,942,080)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.33)	$ (0.25)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	17,848,238	11,977,778

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock [Member]Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Settlement of Preferred Stock [Member]Series E Preferred Stock [Member]	Common Stock [Member]Series E Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]Settlement of Preferred Stock [Member]Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock Subscription [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]Series E Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Settlement of Preferred Stock [Member]Series E Preferred Stock [Member]	Series E Preferred Stock [Member]	Series C Preferred Stock [Member]	Total
Balance at Dec. 31, 2017					$ 11,728					$ 53,233,228	$ (56,524,786)	$ 29,985			$ 1						$ (3,249,844)
Balance (in Shares) at Dec. 31, 2017					11,728,482										1,334
Fair value reclassification											3,044,162										3,044,162
Common stock issued for services					$ 40					141,960											142,000
Common stock issued for services (in Shares)					40,000
Sale of common stock					$ 80					299,905		(29,985)									270,000
Sale of common stock (in Shares)					80,000
Common stock issued upon conversion of preferred stock and accrued dividends	$ 3	$ 84	$ 259	$ 5		$ 8,273	$ 261,951	$ (259)	$ 19,995								$ 8,276	$ 262,035		$ 20,000
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)	2,638	83,830	258,800	5,334									(647)
Sale of Series D preferred stock								$ 1,492,968						$ 1					$ 1,492,969
Sale of Series D preferred stock (in Shares)														1,000
Common stock subscription received												115,470									115,470
Stock based compensation										246,710											246,710
Preferred Stock dividend										(305,046)											(305,046)
Net loss											(2,637,034)										(2,637,034)
Balance at Mar. 31, 2018					$ 12,199					55,399,685	(56,117,658)	115,470			$ 1	$ 1					(590,302)
Balance (in Shares) at Mar. 31, 2018					12,199,084										687	1,000
Balance at Dec. 31, 2017					$ 11,728					53,233,228	(56,524,786)	29,985			$ 1						(3,249,844)
Balance (in Shares) at Dec. 31, 2017					11,728,482										1,334
Preferred Stock dividend																					(305,046)
Net loss																					(2,637,034)
Balance at Dec. 31, 2018					$ 16,869					74,039,341	(70,731,941)										$ 3,324,269
Balance (in Shares) at Dec. 31, 2018					16,868,783																16,868,783
Balance (in Shares) at Sep. 09, 2018																					40,333,758
Warrant subscription exercise received																					$ 24,200
Balance (in Shares) at Sep. 10, 2018																					16,133,544
Balance (in Shares) at Dec. 31, 2018					16,868,783																16,868,783
Common stock issued for services					$ 560					2,332,640											$ 2,333,200
Common stock issued for services (in Shares)					560,000
Sale of common stock					$ 2,155					8,617,123											$ 8,619,278
Sale of common stock (in Shares)					2,155,127																2,155,127
Common stock issued upon exercise of warrants at an average of $3.86 per share					$ 298					1,150,482											$ 1,150,780
Common stock issued upon exercise of warrants at an average of $3.86 per share (in Shares)					298,319
Common stock issued upon cashless exercise of warrants					$ 105					(105)
Common stock issued upon cashless exercise of warrants (in Shares)					104,424
Warrant subscription exercise received												309,000									309,000
Stock based compensation					$ 23					336,792											336,815
Stock based compensation (in Shares)					23,332
Preferred Stock dividend										(10,541)											(10,541)
Net loss											(5,869,548)										(5,869,548)
Balance at Mar. 31, 2019					$ 20,010					$ 86,465,732	$ (76,601,489)	$ 309,000									$ 10,193,253
Balance (in Shares) at Mar. 31, 2019					20,009,985																20,009,985

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)	Mar. 31, 2018$ / shares
Preferred Stock [Member] | Series E Preferred Stock [Member]
Conversion of preferred stock	$ 1.50
Common stock issued	1.25
Preferred Stock [Member] | Series E Preferred Stock [Member] | Series E Preferred Stock [Member]
Conversion of preferred stock	$ 1.50

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,869,548)	$ (2,637,034)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	7,935	2,903
Equity based compensation	2,670,015	388,710
Changes in operating assets and liabilities:
Prepaid expenses	21,865	(2,173)
Payment of long term deposit	0	(5,393)
Accounts payable	(354,272)	(134,714)
Change in derivative liabilities	1,404	0
Deferred rent payable	0	427
Net cash used in operating activities	(3,522,601)	(2,387,274)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of patent costs	(58,327)	0
Payment of trademark costs	(275)	0
Purchase of property and equipment	(14,422)	(3,644)
Net cash used in investing activity	(73,024)	(3,644)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	8,619,278	270,000
Proceeds from sale of Series E preferred stock	0	1,492,969
Proceeds from exercise of warrants	1,459,780	0
Proceeds from common stock subscription	0	115,470
Net cash provided by financing activities	10,079,058	1,878,439
Net increase in cash and cash equivalents	6,483,433	(512,479)
Cash and cash equivalents, beginning of the period	4,450,160	1,547,579
Cash and cash equivalents, end of the period	10,933,593	1,035,100
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:
Reclassify derivative liability to equity		3,044,162
Dividends payable on preferred stock charged to additional paid in capital	10,541	305,046
Right-to-use assets and lease liability recorded upon adoption of ASC 842	418,838	0
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	0	28,276
Embedded Derivative Financial Instruments, Upon Issuance of Series D Preferred Stock [Member]
Non cash investing and financing activities:
Reclassify derivative liability to equity	0	262,035
Upon Adoption of ASU 2017-11 [Member]
Non cash investing and financing activities:
Reclassify derivative liability to equity	$ 0	$ 3,044,162

NOTE 1 - NATURE OF OPERATIONS A

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. On November 7, 2018, the Company formed NeuroClear Technologies, Inc., a Delaware Corporation, for the purpose to pursue additional applications of the PURE EP™ signal processing technology outside of electrophysiology. As of March 31, 2019, there were no significant assets or liabilities in NeuroClear Technologies, Inc, or operations since its formation. The condensed consolidated financial statements include the accounts of BioSig Technologies, Inc. and its wholly owned subsidiary, NeuroClear Technologies, Inc. to as the “Company” or “BioSig”. The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2018 has been derived from audited financial statements. Operating results for the three months ended March 31, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2018 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 15, 2019. Effective September 10, 2018, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 2.5 shares of common stock. As a result, 40,333,758 shares of the Company’s common stock were exchanged for 16,133,544 shares of the Company's common stock. These financial statements have been retroactively restated to reflect the reverse stock split. (See Note 8)

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of March 31, 2019, the Company had cash of $10,933,593 and working capital of $10,080,879. The Company raised approximately $8,600,000 through the sale of common stock and $1,500,000 from the exercise of previously issued warrants during the three months ended March 31, 2019 and approximately $417,000 subsequent to March 31, 2019 (See Note 13). During the three months ended March 31, 2019, the Company used net cash in operating activities of $3,522,601. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 10 months. The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company will require additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be commercially viable. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2019 and December 31, 2018, the Company did not have any derivative instruments that were designated as hedges. At March 31, 2019 and December 31, 2018, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity. Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,488,839 and $862,420 for the three months ended March 31, 2019 and 2018, respectively. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2019 and December 31, 2018, deposits in excess of FDIC limits were $10,683,593 and $4,200,160, respectively. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2019 and 2018 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2019 March 31, 2018 Series C convertible preferred stock 126,667 257,334 Series D convertible preferred stock - 274,800 Series E convertible preferred stock - 400,000 Options to purchase common stock 3,940,828 3,292,128 Warrants to purchase common stock 3,987,088 4,895,051 Totals 8,054,583 9,119,313 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of March 31, 2019, the Company had 3,940,828 options outstanding to purchase shares of common stock, of which 3,042,512 were vested. As of December 31, 2018, there were outstanding stock options to purchase 3,135,828 shares of common stock, 3,007,946 shares of which were vested. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Patents, net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510 (k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 10 years. During the three months ended March 31, 2019, the Company recorded amortization of $2,726 to current period operations. Registration Rights On March 12, 2019, in connection with the Company’s Private Placement of common stock, the Company also agreed on or prior the date that is 45 calendar days after the closing date of the Private Placement, the Company will be required to use commercially reasonable efforts to prepare and file a registration statement on Form S-3 or Form S-1 with the Securities and Exchange Commission (the “ SEC Adoption of Accounting Standards In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $419,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $419,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. See Note 5. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2019 and December 31, 2018 is summarized as follows: March 31, 2019 December 31, 2018 Computer equipment $ 117,469 $ 105,447 Furniture and fixtures 35,019 32,619 Subtotal 152,488 138,066 Less accumulated depreciation (98,929 ) (93,720 ) Property and equipment, net $ 53,559 $ 44,346 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $5,209 and $2,903 for three months ended March 31, 2019 and 2018, respectively.

NOTE 5 - RIGHT TO USE ASSETS AN

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 5 – RIGHT TO USE ASSETS AND LEASE LIABILITY On May 22, 2018, the Company entered into a fifth lease amendment agreement, whereby the Company agreed to extend the lease for the original office space and expand with additional space in Los Angeles, California, commencing June 14, 2018 and expiring on June 30, 2021 at an initial rate of $14,731 per month with escalating payments. In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $1,070 per month. In addition, the Company entered into a lease for storage space with the Los Angeles, California building commencing on December 1, 2017 and expiring on August 31, 2019 for approximately $223 per month. The Company has an option to extend the lease for an additional 3 year (option) term. On April 11, 2018, the Company extended a short-term lease agreement whereby the Company leased office space in Austin, Texas commencing on August 1, 2018 and expiring July 31, 2019 for $979 per month. On October 1, 2018, the Company entered into a lease agreement whereby the Company leased office space in Norwalk, Connecticut commencing on October 1, 2018 and expiring September 30, 2019 for $2,000 per month. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. In determining the length of the lease term to its long term lease, the Company determined not to consider an embedded 3 year option primarily due to i) the renewal rate is at future market rate to be determined and ii) Company does not have significant leasehold improvements that would restrict its ability to consider relocation. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8% and determined the initial present value, at inception, of $496,467. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $418,838, lease liability of $422,215 and eliminated deferred rent of $3,377. Right to use assets is summarized below: March 31, 2019 Los Angeles, Suite 740 $ 218,875 Los Angeles, Suite 745 277,592 Subtotal 496,467 Less accumulated depreciation (115,881 ) Right to use assets, net $ 380,586 During the three months ended March 31, 2019, the Company recorded $46,451 as lease expense to current period operations. Lease liability is summarized below: March 31, 2019 Los Angeles, Suite 740 $ 169,885 Los Angeles, Suite 745 215,482 Total lease liability 385,367 Less: short term portion (158,836 ) Long term portion $ 226,531 Maturity analysis under these lease agreements are as follows: Nine months ended December 31, 2019 $ 137,503 Year ended December 31, 2020 189,141 Year ended December 31, 2021 96,196 Total $ 422,840 Less: Present value discount (37,473 ) Lease liability $ 385,367 Lease expense for the three months ended March 31, 2019 was comprised of the following: Operating lease expense $ 46,451 Short-term lease expense 13,238 Variable lease expense 438 $ 60,127

NOTE 6 - ACCOUNTS PAYABLE AND A

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2019 and December 31, 2018 consist of the following: March 31, 2019 December 31, 2018 Accrued accounting and legal $ 94,477 $ 59,439 Accrued reimbursements and travel 26,245 27,853 Accrued consulting 102,967 89,718 Accrued research and development expenses 345,751 351,631 Accrued office and other 3,821 14,304 Accrued payroll and related expenses 10,412 395,000 Deferred rent - 3,377 Accrued settlement related to arbitration 13,333 13,333 $ 597,006 $ 954,655

NOTE 7 - SERIES C 9% CONVERTIBL

NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 7 – SERIES C 9% CONVERTIBLE PREFERRED STOCK Series C 9% Convertible Preferred Stock On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 532,251 warrants to purchase the Company’s common stock at $6.53 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $6.53 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $6.53 per share to $3.75 per share and increased the aggregate number of shares issuable under the warrants to 926,121. Series C Preferred Stock issued and outstanding totaled 475 as of March 31, 2019 and December 31, 2018, respectively. As of March 31, 2019 and December 31, 2018, the Company has accrued $253,449 and $242,908 dividends payable on the Series C Preferred Stock.

NOTE 8 - STOCKHOLDER EQUITY

NOTE 8 - STOCKHOLDER EQUITY	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2019 and December 31, 2018, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock and 1,000 shares of Series E Preferred Stock. As of March 31, 2019 and December 31, 2018, there were no outstanding shares of Series A, Series B, Series D and Series E preferred stock. Common stock On September 10, 2018, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 2.5 shares of common stock. No fractional shares were issued from such aggregation of common stock, upon the reverse split; any fractional share was rounded up and converted to the nearest whole share of common stock. As a result, 40,333,758 of the Company’s common stock were exchanged for 16,133,544 of the Company's common stock resulting in the transfer of $24,200 from common stock to additional paid in capital. These consolidated financial statements have been retroactively restated to reflect the reverse stock split. The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2019 and December 31, 2018, the Company had 20,009,985 and 16,868,783 shares issued and outstanding, respectively. During the three months ended March 31, 2019, the Company issued an aggregate of 560,000 shares of its common stock for services totaling $2,333,200 ($4.17 per share). During the three months ended March 31, 2019, the Company issued an aggregate of 23,332 shares of its common stock for vested restricted stock units. During the three months ended March 31, 2019, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,155,127 shares of common stock for aggregate proceeds of $8,619,278, net of $1,230 in expenses During the three months ended March 31, 2019, the Company issued 298,319 shares of common stock in exchange for proceeds of $1,150,780 from the exercise of warrants. During the three months ended March 31, 2019, the Company issued 104,424 shares of common stock in exchange for the exercise of 210,144 cashless exercises of warrants. At March 31, 2019, the Company had received proceeds of $309,000 for the exercise of warrants.

NOTE 9 - OPTIONS, RESTRICTED ST

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 910,346 shares of its common stock for future issuance under the terms of the Plan. During the three months ended March 31, 2019, the Company granted an aggregate of 805,000 options to officers, directors and key consultants. The following table presents information related to stock options at March 31, 2019: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.51-5.00 1,663,218 8.1 1,163,218 5.01-7.500 2,157,610 4.3 1,759,294 7.51-10.00 120,000 6.0 120,000 3,940,828 6.0 3,042,512 A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2019 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2018 3,135,828 $ 5.34 5.2 $ 311,545 Grants 805,000 4.90 10.0 $ - Exercised - Canceled - Outstanding at March 31, 2019 3,940,828 $ 5.25 6.0 $ 4,162,880 Exercisable at March 31, 2019 3,042,512 $ 5.36 4.8 $ 3,020,099 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $6.14 as of March 31, 2019, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the three months ended March 31, 2019 was estimated using the Black-Scholes pricing model. On January 22, 2019, the Company granted an aggregate of 460,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $4.33 per share for a term of ten years with vesting quarterly beginning April 1, 2019 over 3 years On March 14, 2019, the Company granted an aggregate of 345,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $5.66 per share for a term of ten years with 150,000 options vesting at anniversary date beginning March 14, 2020 over 3 years, 175,000 options vesting quarterly beginning June 14, 2019 over 3 years and 20,000 options vesting at one year anniversary. The following assumptions were used in determining the fair value of options during the three months ended March 31, 2019: Risk-free interest rate 2.53% - 2.74 % Dividend yield 0 % Stock price volatility 90.73% to 91.55 % Expected life 6 – 10 years Weighted average grant date fair value $ 4.244 The fair value of all options vesting during the three months ended March 31, 2019 and 2018 of $193,234 and $246,710, respectively, was charged to current period operations. Unrecognized compensation expense of $3,472,040 and $173,446 at March 31, 2019 and December 31, 2018, respectively, will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the three months ended March 31, 2019: Total restricted shares issued as of December 31, 2018 - Granted 190,000 Vested and issued (23,332 ) Vested restricted shares as of March 31, 2019 - Unvested restricted shares as of March 31, 2019 166,668 On February 28, 2019, the Company granted an aggregate of 70,000 restricted stock grants for services with 23,332 vested immediately; 23,334 vesting at one year anniversary and 23,334 vesting at two year anniversary. On March 20, 2019, the Company granted an aggregate of 120,000 restricted stock grants for services vesting quarterly beginning on April 1, 2019 over one year. Stock based compensation expense related to restricted stock grants was $143,581 and $0 for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019, the stock-based compensation relating to restricted stock of $1,063,717 remains unamortized. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2019: Exercise Number Expiration Price Outstanding Date $ 0.0025 153,328 January 2020 $ 3.75 1,977,295 April 2019 to August 2021 $ 4.375 633,272 May 2021 $ 4.60 12,294 January 2020 $ 4.875 352,943 April 2019 to September 2019 $ 5.05 12,227 January 2020 $ 6.85 217,958 July 2021 to August 2021 $ 6.875 91,504 August 2019 to September 2019 $ 9.375 536,267 April 2019 to March 2020 3,987,088 A summary of the warrant activity for the three months ended March 31, 2019 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2018 4,579,511 $ 4.73 1.5 $ 1,924,388 Grants - Exercised (508,463 ) $ 3.81 Expired (83,960 ) $ 6.61 - - Outstanding at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244 Vested and expected to vest at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244 Exercisable at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $6.14 of March 31, 2019, which would have been received by the option holders had those option holders exercised their options as of that date.

NOTE 10 - RELATED PARTY TRANSAC

NOTE 10 - RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 10 – RELATED PARTY TRANSACTIONS The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009. No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net amount of outstanding advances at March 31, 2019 and December 31, 2018 was $-0-. At March 31, 2019 and December 31, 2018, the Company had reimbursable travel and other related expenses due related parties of $14,632 and $32,366, respectively. On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options are performance conditioned. Mr. Filler is the general counsel and partner of Sherpa. During the three months ended March 31, 2019 and 2018, the Company paid $75,000 and $175,000 as patent costs, consulting fees and expense reimbursements. As of March 31, 2019 and December 31, 2018, there was an unpaid balance of $0.

NOTE 11 - FAIR VALUE MEASUREMEN

NOTE 11 - FAIR VALUE MEASUREMENT	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 11 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of March 31, 2019 and December 31, 2018, the Company did not have any items that would be classified as level 1 or 2 disclosures. As of March 31, 2019 and December 31, 2018, the Company did not have any derivative instruments that were designated as hedges. There were no derivative and warrant liability as of March 31, 2019 and December 31, 2018.

NOTE 12 - SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 – SUBSEQUENT EVENTS In April 2019, the Company issued an aggregate of 167,327 shares of its common stock in exchange for warrant subscriptions received of $309,000 and proceeds of $416,719 from the exercise of warrants. On April 2, 2019, the Company issued 244 shares of its common stock in exchange for the cashless exercise of 600 warrants. In April 2019, the Company issued an aggregate of 30,000 shares of its common stock for vested restricted stock units. Series C conversions On April 1, 2019 the Company issued 3,507 shares of its common stock in exchange for 10 shares of Series C preferred stock and accrued dividends.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2019 and December 31, 2018, the Company did not have any derivative instruments that were designated as hedges. At March 31, 2019 and December 31, 2018, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,488,839 and $862,420 for the three months ended March 31, 2019 and 2018, respectively.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2019 and December 31, 2018, deposits in excess of FDIC limits were $10,683,593 and $4,200,160, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2019 and 2018 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2019 March 31, 2018 Series C convertible preferred stock 126,667 257,334 Series D convertible preferred stock - 274,800 Series E convertible preferred stock - 400,000 Options to purchase common stock 3,940,828 3,292,128 Warrants to purchase common stock 3,987,088 4,895,051 Totals 8,054,583 9,119,313
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of March 31, 2019, the Company had 3,940,828 options outstanding to purchase shares of common stock, of which 3,042,512 were vested. As of December 31, 2018, there were outstanding stock options to purchase 3,135,828 shares of common stock, 3,007,946 shares of which were vested.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents, net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510 (k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 10 years. During the three months ended March 31, 2019, the Company recorded amortization of $2,726 to current period operations.
Registration Rights Policy [Policy Text Block]	Registration Rights On March 12, 2019, in connection with the Company’s Private Placement of common stock, the Company also agreed on or prior the date that is 45 calendar days after the closing date of the Private Placement, the Company will be required to use commercially reasonable efforts to prepare and file a registration statement on Form S-3 or Form S-1 with the Securities and Exchange Commission (the “ SEC
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Accounting Standards In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $419,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $419,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. See Note 5. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 3 - SUMMARY OF SIGNIFICA_2

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2019 March 31, 2018 Series C convertible preferred stock 126,667 257,334 Series D convertible preferred stock - 274,800 Series E convertible preferred stock - 400,000 Options to purchase common stock 3,940,828 3,292,128 Warrants to purchase common stock 3,987,088 4,895,051 Totals 8,054,583 9,119,313

NOTE 4 - PROPERTY AND EQUIPME_2

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2019 and December 31, 2018 is summarized as follows: March 31, 2019 December 31, 2018 Computer equipment $ 117,469 $ 105,447 Furniture and fixtures 35,019 32,619 Subtotal 152,488 138,066 Less accumulated depreciation (98,929 ) (93,720 ) Property and equipment, net $ 53,559 $ 44,346

NOTE 5 - RIGHT TO USE ASSETS _2

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Right to Use Asset [Table Text Block]	Right to use assets is summarized below: March 31, 2019 Los Angeles, Suite 740 $ 218,875 Los Angeles, Suite 745 277,592 Subtotal 496,467 Less accumulated depreciation (115,881 ) Right to use assets, net $ 380,586
Lessee, Operating Lease, Disclosure [Table Text Block]	Lease liability is summarized below: March 31, 2019 Los Angeles, Suite 740 $ 169,885 Los Angeles, Suite 745 215,482 Total lease liability 385,367 Less: short term portion (158,836 ) Long term portion $ 226,531
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Maturity analysis under these lease agreements are as follows: Nine months ended December 31, 2019 $ 137,503 Year ended December 31, 2020 189,141 Year ended December 31, 2021 96,196 Total $ 422,840 Less: Present value discount (37,473 ) Lease liability $ 385,367
Lease, Cost [Table Text Block]	Lease expense for the three months ended March 31, 2019 was comprised of the following: Operating lease expense $ 46,451 Short-term lease expense 13,238 Variable lease expense 438 $ 60,127

NOTE 6 - ACCOUNTS PAYABLE AND_2

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at March 31, 2019 and December 31, 2018 consist of the following: March 31, 2019 December 31, 2018 Accrued accounting and legal $ 94,477 $ 59,439 Accrued reimbursements and travel 26,245 27,853 Accrued consulting 102,967 89,718 Accrued research and development expenses 345,751 351,631 Accrued office and other 3,821 14,304 Accrued payroll and related expenses 10,412 395,000 Deferred rent - 3,377 Accrued settlement related to arbitration 13,333 13,333 $ 597,006 $ 954,655

NOTE 9 - OPTIONS, RESTRICTED _2

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2019: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.51-5.00 1,663,218 8.1 1,163,218 5.01-7.500 2,157,610 4.3 1,759,294 7.51-10.00 120,000 6.0 120,000 3,940,828 6.0 3,042,512
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2019 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2018 3,135,828 $ 5.34 5.2 $ 311,545 Grants 805,000 4.90 10.0 $ - Exercised - Canceled - Outstanding at March 31, 2019 3,940,828 $ 5.25 6.0 $ 4,162,880 Exercisable at March 31, 2019 3,042,512 $ 5.36 4.8 $ 3,020,099
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of options during the three months ended March 31, 2019: Risk-free interest rate 2.53% - 2.74 % Dividend yield 0 % Stock price volatility 90.73% to 91.55 % Expected life 6 – 10 years Weighted average grant date fair value $ 4.244
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the three months ended March 31, 2019: Total restricted shares issued as of December 31, 2018 - Granted 190,000 Vested and issued (23,332 ) Vested restricted shares as of March 31, 2019 - Unvested restricted shares as of March 31, 2019 166,668
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2019: Exercise Number Expiration Price Outstanding Date $ 0.0025 153,328 January 2020 $ 3.75 1,977,295 April 2019 to August 2021 $ 4.375 633,272 May 2021 $ 4.60 12,294 January 2020 $ 4.875 352,943 April 2019 to September 2019 $ 5.05 12,227 January 2020 $ 6.85 217,958 July 2021 to August 2021 $ 6.875 91,504 August 2019 to September 2019 $ 9.375 536,267 April 2019 to March 2020 3,987,088
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the three months ended March 31, 2019 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2018 4,579,511 $ 4.73 1.5 $ 1,924,388 Grants - Exercised (508,463 ) $ 3.81 Expired (83,960 ) $ 6.61 - - Outstanding at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244 Vested and expected to vest at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244 Exercisable at March 31, 2019 3,987,088 $ 4.81 1.2 $ 7,263,244

NOTE 1 - NATURE OF OPERATIONS_2

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) - shares	Sep. 10, 2018	Mar. 31, 2019	Dec. 31, 2018	Sep. 09, 2018
Disclosure Text Block [Abstract]
Stockholders' Equity, Reverse Stock Split	1 share for every 2.5 shares of common stock
Common Stock, Shares, Outstanding	16,133,544	20,009,985	16,868,783	40,333,758

NOTE 2 - GOING CONCERN AND MA_2

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 15, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value		$ 10,933,593	$ 1,035,100	$ 4,450,160	$ 1,547,579
Working Capital (Deficit)		10,080,879
Proceeds from Warrant Exercises		1,500,000
Net Cash Provided by (Used in) Operating Activities		$ (3,522,601)	$ (2,387,274)
Subsequent Event [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Warrant Exercises	$ 417,000

NOTE 3 - SUMMARY OF SIGNIFICA_3

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jan. 01, 2019
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Research and Development Expense	$ 1,488,839	$ 862,420	$ 862,420
Cash, Uninsured Amount	$ 10,683,593		$ 4,200,160
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	3,940,828		3,135,828
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in Shares)	3,042,512		3,007,946
Amortization of Intangible Assets	$ 2,726
Operating Lease, Liability, Current	158,836			$ 419,000
Operating Lease, Right-of-Use Asset	$ 380,586		$ 0	$ 418,838
Patents [Member]
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years

NOTE 3 - SUMMARY OF SIGNIFICA_4

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	8,054,583	9,119,313
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	126,667	257,334
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	274,800
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	400,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	3,940,828	3,292,128
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	3,987,088	4,895,051

NOTE 4 - PROPERTY AND EQUIPME_3

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 5,209	$ 2,903
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 4 - PROPERTY AND EQUIPME_4

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 152,488	$ 138,066
Less accumulated depreciation	(98,929)	(93,720)
Property and equipment, net	53,559	44,346
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	117,469	105,447
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 35,019	$ 32,619

NOTE 5 - RIGHT TO USE ASSETS _3

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - USD ($)	Oct. 01, 2018	May 22, 2018	Apr. 11, 2018	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Right-of-Use Asset				$ 380,586	$ 418,838	$ 0
Operating Lease, Liability				385,367	$ 422,215
Deferred Rent, Elimination				3,377
Operating Leases, Rent Expense				$ 46,451
Office Building [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Lease Expiration Date	Sep. 30, 2019	Jun. 30, 2021	Jul. 31, 2019
Operating Leases, Rent Expense, Minimum Rentals	$ 2,000	$ 14,731	$ 979
Operating Lease, Right-of-Use Asset		496,467
Parking Spaces [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals		$ 1,070
Storage Space [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Lease Expiration Date		Aug. 31, 2019
Operating Leases, Rent Expense, Minimum Rentals		$ 223
Lessor, Operating Lease, Option to Extend		The Company has an option to extend the lease for an additional 3 year (option) term.

NOTE 5 - RIGHT TO USE ASSETS _4

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Assets - USD ($)	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Assets [Line Items]
Right to use assets, gross	$ 496,467
Less accumulated depreciation	(115,881)
Right to use assets, net	380,586	$ 418,838	$ 0
Los Angeles, Suite 740 [Member] | Building [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Assets [Line Items]
Right to use assets, gross	218,875
Los Angeles, Suite 745 [Member] | Building [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Assets [Line Items]
Right to use assets, gross	$ 277,592

NOTE 5 - RIGHT TO USE ASSETS _5

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Leased Assets [Line Items]
Lease liability	$ 385,367	$ 422,215
Short term portion	(158,836)	$ (419,000)
Long term portion	226,531		$ 0
Los Angeles, Suite 740 [Member] | Building [Member]
Operating Leased Assets [Line Items]
Lease liability	169,885
Los Angeles, Suite 745 [Member] | Building [Member]
Operating Leased Assets [Line Items]
Lease liability	$ 215,482

NOTE 5 - RIGHT TO USE ASSETS _6

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] - USD ($)	Mar. 31, 2019	Jan. 01, 2019
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] [Abstract]
Nine months ended December 31, 2019	$ 137,503
Year ended December 31, 2020	189,141
Year ended December 31, 2021	96,196
Total	422,840
Less: Present value discount	(37,473)
Lease liability	$ 385,367	$ 422,215

NOTE 5 - RIGHT TO USE ASSETS _7

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lease Cost	3 Months Ended
	Mar. 31, 2019USD ($)
Lease, Cost [Abstract]
Operating lease expense	$ 46,451
Short-term lease expense	13,238
Variable lease expense	438
Lease cost	$ 60,127

NOTE 6 - ACCOUNTS PAYABLE AND_3

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 94,477	$ 59,439
Accrued reimbursements and travel	26,245	27,853
Accrued consulting	102,967	89,718
Accrued research and development expenses	345,751	351,631
Accrued office and other	3,821	14,304
Accrued payroll and related expenses	10,412	395,000
Deferred rent	0	3,377
Accrued settlement related to arbitration	13,333	13,333
	$ 597,006	$ 954,655

NOTE 7 - SERIES C 9% CONVERTI_2

NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Jan. 09, 2013	Mar. 31, 2019	Dec. 31, 2018
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted	532,251	0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 6.53
Warrants, Term of Warrants	5 years
Warrant, Description of Warrant	The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $6.53 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.
Class of Warrant or Right, Outstanding		3,987,088	4,579,511
Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized	4,200
Preferred Stock, Dividend Rate, Percentage	9.00%
Temporary Equity, Par Value (in Dollars)	$ 1,000
Preferred Stock, Dividend Payment Terms	payable quarterly
Preferred Stock, Voting Rights	The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description	The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.
Temporary Equity, Shares Issued		475	475
Dividends Payable (in Dollars)		$ 253,449	$ 242,908
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 3.75
Class of Warrant or Right, Outstanding	926,121

NOTE 8 - STOCKHOLDER EQUITY (De

NOTE 8 - STOCKHOLDER EQUITY (Details) - USD ($)	Sep. 10, 2018	Mar. 31, 2019	Dec. 31, 2018	Sep. 09, 2018
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001	$ 0.001
Stockholders' Equity, Reverse Stock Split	1 share for every 2.5 shares of common stock
Common Stock, Shares, Issued	16,133,544	20,009,985	16,868,783	40,333,758
Adjustments to Additional Paid in Capital, Other (in Dollars)	$ 24,200	$ 309,000
Common Stock, Shares Authorized		200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	16,133,544	20,009,985	16,868,783	40,333,758
Stock Issued During Period, Shares, Conversion of Units		23,332
Stock Issued During Period, Shares, New Issues		2,155,127
Proceeds from Issuance or Sale of Equity (in Dollars)		$ 8,619,278
Payments of Stock Issuance Costs (in Dollars)		1,230
Proceeds from Warrant Exercises (in Dollars)		$ 1,500,000
Class of Warrant or Rights, Exercised		508,463
Proceeds from Warrant Subscriptions (in Dollars)		$ 309,000
Series A Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		200	200
Series B Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		600	600
Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		4,200	4,200
Series D Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		1,400	1,400
Series E Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized		1,000	1,000
Preferred Stock, Shares Outstanding		0
Stock in Exchange for Proceeds of Exercise of Warrants [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		298,319
Proceeds from Warrant Exercises (in Dollars)		$ 1,150,780
Cashless Exercise of Warrants [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		104,424
Class of Warrant or Rights, Exercised		210,144
2012 Equity Incentive Plan [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		560,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)		$ 2,333,200
Shares Issued, Price Per Share (in Dollars per share)		$ 4.17

NOTE 9 - OPTIONS, RESTRICTED _3

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)	Mar. 20, 2019	Mar. 14, 2019	Feb. 28, 2019	Jan. 22, 2019	Jan. 09, 2013	Oct. 19, 2012	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Nov. 06, 2017
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							805,000
Share Price (in Dollars per share)							$ 6.14
Class of Warrant or Rights, Granted					532,251		0
Share-based Compensation (in Dollars)							$ 2,670,015	$ 388,710
Restricted Stock [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation (in Dollars)							$ 143,581		$ 0
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent (in Dollars)										$ 1,063,717
Warrants at $2.10 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted			70,000
Shares Issued for Services [Member] | Restricted Stock [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting quarterly beginning on April 1, 2019 over one year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	120,000
Shares Issued for Services [Member] | Share-based Compensation Award, Tranche One [Member] | Restricted Stock [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			immediately
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			23,332
Shares Issued for Services [Member] | Share-based Compensation Award, Tranche Two [Member] | Restricted Stock [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			one year anniversary
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			23,334
Shares Issued for Services [Member] | Share-based Compensation Award, Tranche Three [Member] | Restricted Stock [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			two year anniversary
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			23,334
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						15,186,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award						the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Common Stock, Capital Shares Reserved for Future Issuance						910,346
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							805,000
Share Price (in Dollars per share)							$ 6.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)							$ 193,234	$ 246,710
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)							$ 3,472,040		$ 173,446
2012 Equity Incentive Plan [Member] | Maximum [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						10 years
2012 Equity Incentive Plan [Member] | Services Provided [Member] | Options at $4.33 [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				460,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)				$ 4.33
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
2012 Equity Incentive Plan [Member] | Services Provided [Member] | Options at $5.66 [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		345,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)		$ 5.66
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
2012 Equity Incentive Plan [Member] | Services Provided [Member] | Options at $5.66 [Member] | Share-based Compensation Award, Tranche One [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		150,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting at anniversary date beginning March 14, 2020 over 3 years, 175,000 options vesting quarterly beginning June 14, 2019 over 3 years
2012 Equity Incentive Plan [Member] | Services Provided [Member] | Options at $5.66 [Member] | Share-based Compensation Award, Tranche Two [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		175,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting quarterly beginning June 14, 2019 over 3 years
2012 Equity Incentive Plan [Member] | Services Provided [Member] | Options at $5.66 [Member] | Share-based Compensation Award, Tranche Three [Member] | Employee Stock Option [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		20,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting at one year anniversary

NOTE 9 - OPTIONS, RESTRICTED _4

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	3,940,828	3,135,828
Options Outstanding, Weighted Average Remaining Life	6 years	5 years 73 days
Options Exercisable, Number of Options	3,042,512
Options at $2.51-$5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.51
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 5
Options Outstanding, Number of Options	1,663,218
Options Outstanding, Weighted Average Remaining Life	8 years 36 days
Options Exercisable, Number of Options	1,163,218
Options at $5.01-$7.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 5.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 7.500
Options Outstanding, Number of Options	2,157,610
Options Outstanding, Weighted Average Remaining Life	4 years 109 days
Options Exercisable, Number of Options	1,759,294
Options at $7.51-$10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 7.51
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 10
Options Outstanding, Number of Options	120,000
Options Outstanding, Weighted Average Remaining Life	6 years
Options Exercisable, Number of Options	120,000

NOTE 9 - OPTIONS, RESTRICTED _5

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	3,940,828	3,135,828
Options Outstanding, Weighted-Average Exercise Price	$ 5.25	$ 5.34
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years	5 years 73 days
Options Outstanding, Aggregate Intrinsic Value	$ 4,162,880	$ 311,545
Options Exercisable, Shares	3,042,512
Options Exercisable, Weighted-Average Exercise Price	$ 5.36
Options Exercisable, Weighted-Average Remaining Contractual Term	4 years 292 days
Options Exercisable, Aggregate Intrinsic Value	$ 3,020,099
Options Granted, Shares	805,000
Options Granted, Weighted-Average Exercise Price	$ 4.90
Options Granted, Weighted-Average Remaining Contractual Term	10 years
Options Exercised, Shares	0
Options Canceled, Shares	0

NOTE 9 - OPTIONS, RESTRICTED _6

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	3 Months Ended
	Mar. 31, 2019$ / shares
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%
Weighted average grant date fair value (in Dollars per share)	$ 4.244
Minimum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Stock price volatility	90.73%
Expected life	6 years
Maximum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Stock price volatility	91.55%
Expected life	10 years

NOTE 9 - OPTIONS, RESTRICTED _7

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2019shares
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued	0
Restricted shares Granted	190,000
Restricted shares Vested	(23,332)
Unvested restricted shares	166,668

NOTE 9 - OPTIONS, RESTRICTED _8

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Jan. 09, 2013
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)			$ 6.53
Number of Warrants Outstanding	3,987,088	4,579,511
Warrants at $0.0025 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 0.0025
Number of Warrants Outstanding	153,328
Expiration Date, Warrants	January 2020
Warrants at $3.75 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.75
Number of Warrants Outstanding	1,977,295
Expiration Date, Warrants	April 2019 to August 2021
Warrants at $4.375 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.375
Number of Warrants Outstanding	633,272
Expiration Date, Warrants	May 2021
Warrants at $4.6 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.60
Number of Warrants Outstanding	12,294
Expiration Date, Warrants	January 2020
Warrants at $4.875 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.875
Number of Warrants Outstanding	352,943
Expiration Date, Warrants	April 2019 to September 2019
Warrants at $5.05 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 5.05
Number of Warrants Outstanding	12,227
Expiration Date, Warrants	January 2020
Warrants at $6.85 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 6.85
Number of Warrants Outstanding	217,958
Expiration Date, Warrants	July 2021 to August 2021
Warrants at $6.875 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 6.875
Number of Warrants Outstanding	91,504
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $9.375 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 9.375
Number of Warrants Outstanding	536,267
Expiration Date, Warrants	April 2019 to March 2020

NOTE 9 - OPTIONS, RESTRICTED _9

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	Jan. 09, 2013	Mar. 31, 2019	Dec. 31, 2018
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares		3,987,088	4,579,511
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 4.81	$ 4.73
Warrants Outstanding, Weighted-Average Remaining Contractual Term		1 year 73 days	1 year 6 months
Warrants Outstanding, Aggregate Intrinsic Value (in Dollars)		$ 7,263,244	$ 1,924,388
Warrants Vested and expected to vest, Shares		3,987,088
Warrants Vested and expected to vest, Weighted-Average Exercise Price (in Dollars per share)		$ 4.81
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term		1 year 73 days
Warrants Vested and expected to vest, Aggregate Intrinsic Value (in Dollars)		$ 7,263,244
Warrants Exercisable, Shares		3,987,088
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)		$ 4.81
Warrants Exercisable, Weighted-Average Remaining Contractual Term		1 year 73 days
Warrants Exercisable, Aggregate Intrinsic Value (in Dollars)		$ 7,263,244
Warrants Granted, Shares	532,251	0
Warrants Exercised, Shares		(508,463)
Warrants Exercised, Weighted-Average Exercise Price (in Dollars per share)		$ 3.86
Warrants Canceled, Shares		(83,960)
Warrants Canceled, Weighted-Average Exercise Price (in Dollars per share)		$ 6.61

NOTE 10 - RELATED PARTY TRANS_2

NOTE 10 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Nov. 01, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
NOTE 10 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current		$ 14,632		$ 32,366
Related Party Transaction, Description of Transaction	Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing.
Related Party Costs		75,000	$ 175,000
Affiliated Entity [Member]
NOTE 10 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction	Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options are performance conditioned.
Director #2 [Member]
NOTE 10 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due from Other Related Parties, Current		$ 0
Patent Costs, Consulting Fees and Expense Reimbursements [Member]
NOTE 10 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due from Other Related Parties, Current				$ 0

NOTE 12 - SUBSEQUENT EVENTS (De

NOTE 12 - SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)	Apr. 02, 2019	Apr. 01, 2019	Apr. 15, 2019
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	244		167,327
Proceeds from Warrant Subscriptions (in Dollars)			$ 309,000
Proceeds from Issuance of Warrants (in Dollars)			$ 416,719
Class of Warrant or Rights, Exercised	600
Stock Issued During Period, Shares, Conversion of Units			30,000
Series C Preferred Stock [Member]
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued		3,507
Conversion of Stock, Shares Converted		10